PerMED AI - About the company
PerMED AI is an unfunded company. It operates as a Developer of transcriptome analysis tools ranking cancer therapies by pathway. PerMED AI has not raised any funding yet. The company has 467 active competitors, including 128 funded and 100 that have exited. Its top competitors include companies like Guardant Health, Natera and BillionToOne.
Company Details
Developer of transcriptome analysis tools ranking cancer therapies by pathway. This process utilizes paired RNA and DNA sequencing from tumor specimens to measure pathway activation levels. The platform identifies active drivers that standard mutation panels may overlook by normalizing gene expression against reference tissue. Results provide a ranked list of systemic agents based on the underlying biological signals found within the tumor transcriptome. This analysis serves as clinical decision support for molecular tumor boards, providing evidence on contributing genes and signaling interactions to assist in therapy selection. The workflow integrates genomic and transcriptomic data from a single specimen to determine target pathway activity.
Key Metrics
Sign up to download PerMED AI's company profile
PerMED AI's funding and investors
PerMED AI has not raised any funding rounds yet.
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
PerMED AI's Competitors and alternates
Top competitors of PerMED AI include Guardant Health, Natera and BillionToOne. Here is the list of Top 10 competitors of PerMED AI, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Guardant Health 2012, Redwood City (United States), Public | Developer of digital sequencing technology for cancer detection | $557M | 80/100 | |
2nd | Natera 2004, Redwood City (United States), Public | Developer of cell-free DNA testing for oncology, women’s health, and organ health | $152M | 79/100 | |
3rd | BillionToOne 2015, San Francisco (United States), Public | Provider of cell-free cancer liquid biopsy test | $389M | 71/100 | |
4th | Caris Life Sciences 1996, Irving (United States), Public | Developer of panomic disease profiling technologies for cancer precision medicine | $1.23B | 67/100 | |
5th | Foundation Medicine 2010, Cambridge (United States), Acquired | Provider of genomics-based diagnostics test for cancer | $96.5M | 66/100 | |
6th | Myriad Genetics 1991, United States, Public | Developer of molecular diagnostics and personalized medicine for cancer | - | 66/100 | |
7th | Online platform for genetic and diagnostic health testing that helps identify health risks | $67.6M | 65/100 | ||
8th | NeoGenomics 2002, Fort Myers (United States), Public | Provider of cancer genetic diagnostic services | - | 65/100 | |
9th | Saga Diagnostics 2016, Morrisville (United States), Acquired | Provider of tests for detection and analysis of circulating tumor DNA | $17.9M | 65/100 | |
10th | Foresight Diagnostics 2020, Aurora (United States), Acquired | Developer of minimally-invasive liquid biopsy test for the detection of cancer | $104M | 62/100 | |
502nd | ![]() PerMED AI Unfunded | Developer of transcriptome analysis tools ranking cancer therapies by pathway | - | - | 16/100 |
Looking for more details on PerMED AI's competitors? Click here to see the top ones
PerMED AI's Investments and acquisitions
PerMED AI has made no investments or acquisitions yet.
Reports related to PerMED AI
Here is the latest report on PerMED AI's sector:
Are you a Founder ?
FAQs about PerMED AI
Explore our recently published companies
- Panya Advisory - Unfunded company
- Peaufignole - Rennes based, 2025 founded, Unfunded company
- Qipeo Labs - Kenya based, Unfunded company
- QD Academy (Prev. named QuickDesk) - Singapore based, 2014 founded, Unfunded company
- Multibingos - Unfunded company
- Resin Driveways Darlington - Darlington based, 1883 founded, Unfunded company
